1. Clinical study of effect of ezetimibe combined with statins on residual lipoprotein cholesterol and MACE events in patients undergoing emergency intervention with acute coronary syndrome
Yifan DENG ; Yifan DENG ; Shenghu HE ; Daxin WANG ; Chengye DAI ; Xiaoting XU ; Jing ZHANG ; Chengye DAI ; Xiaoting XU
Chinese Journal of Clinical Pharmacology and Therapeutics 2021;26(9):1048-1052
AIM: To investigate the effect of ezetimibe combined with statins on residual lipoprotein-cholesterol (RLP-C) levels and major cardiovascular adverse events (MACE) in patients with acute coronary syndrome (ACS) after emergency intervention (PCI). METHODS: A total of 90 hospitalized patients with ACS and undergoing emergency PCI were randomly divided into two groups: 48 patients in the control group received atorvastatin, and 42 patients in the study group were additionally treated with ezetimibe. RLP-C level before and after treatment was detected. The occurrence of MACE events and adverse drug events during the treatment were obtained through regular follow-up. RESULTS: Compared with the control group, the level of RLP-C in the study group was significantly decreased (P<0.05), the incidence of MACE were significantly decreased (P<0.05), and adverse drug events were not increased. CONCLUSION: The combination therapy of ezedemibe and statins can reduce RLP-C level and MACE in ACS patients undergoing emergency PCI with less adverse reactions, which is worthy of promotion and application.
Result Analysis
Print
Save
E-mail